Imidazopyridine BTK Inhibitors for Selective Kinase Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies lack effective inhibitors for Bruton's Tyrosine Kinase (BTK), which is implicated in autoimmune and inflammatory diseases, as well as certain cancers, limiting treatment options for B-cell mediated disorders.

Innovation Solution

Development of imidazo pyridine compounds that act as selective inhibitors of BTK, capable of modulating BTK activity to treat various diseases associated with BTK, including autoimmune disorders, inflammatory diseases, and cancers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used for BTK inhibition, then treatment options are limited, but no effective BTK inhibitors are available

Engineering Contradiction:

Improveeffectiveness of BTK inhibitionVSAvoidavailability of treatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent segments the broad target of protein kinases into the specific BTK enzyme, designing compounds that selectively inhibit BTK while sparing other kinases. This is achieved through specific molecular structure design (formula I compounds) that target the unique ATP-binding pocket of BTK, resolving the contradiction by providing reliable BTK inhibition without off-target effects that would limit therapeutic versatility

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs parameter changes in the chemical structure of inhibitors (modifying R1, R2, R3 substituents in formula I) to optimize BTK binding affinity and selectivity. By systematically varying these chemical parameters, the invention generates multiple compounds with different potency profiles, thereby expanding treatment options while maintaining reliable BTK inhibition

Inventive Principle:

Principle #35Parameter changes

2Reliability

If BTK activity is inhibited to treat autoimmune and inflammatory diseases, then B-cell mediated disease processes are blocked, but off-target effects on other kinases may occur

Engineering Contradiction:

Improveefficacy in blocking B-cell mediated diseaseVSAvoidoff-target kinase inhibition

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing compounds with specific structural features (formula I with particular R1, R2, R3 configurations) that interact with unique residues in the BTK ATP-binding pocket. This localized molecular design ensures high selectivity for BTK over other kinases, achieving reliable B-cell disease blockade without harmful off-target effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses the ATP-binding pocket of BTK as an intermediary target - by inhibiting this specific site, the compounds block BTK activity and thereby prevent B-cell mediated disease processes. The selective targeting of this intermediary site ensures efficacy while avoiding broader kinase inhibition that would cause harmful side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP3204382B1Heteroaryl compounds as BTK inhibitors and uses thereof

Publication Date: 2021.12.01 MERCK PATENT GMBH

AI summary

The present invention relates to imidazopyridine compounds of formula I, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.